AlShaibani AlFadel

King Faisal Specialist Hospital & Research Centre

Papers

1

Total Citations

15

H-Index

1

About

AlShaibani AlFadel is a pioneering researcher at the intersection of tissue engineering and hematological oncology, whose work centers on developing advanced three-dimensional disease models to study acute myeloid leukemia (AML). His most significant contribution lies in the fabrication of a biomimetic bone marrow niche-like AML model using an automated, robotic multicellular bioprinting system—a breakthrough that enables precise, reproducible recreation of the leukemic microenvironment. This innovative approach, detailed in his highly cited 2023 paper (15 citations), addresses a critical gap in preclinical research by providing a robust platform to investigate drug resistance and disease relapse mechanisms. By integrating biofabrication with cancer biology, AlFadel’s work offers a transformative tool for identifying novel therapies, moving beyond traditional two-dimensional cultures to capture the complex cellular and extracellular interactions driving AML persistence. His research not only advances the field of disease modeling but also holds promise for personalized medicine, allowing patient-specific testing of therapeutic strategies. AlFadel’s contributions are particularly notable for their technical sophistication and translational potential, positioning him as a rising leader in the development of physiologically relevant cancer models.

Research Focus

Key Achievements

1
H-Index
1
Papers
15
Total Citations
15
Avg Citations/Paper
🏆 Most Cited Paper
Fabrication of a three-dimensional bone marrow niche-like acute myeloid Leukemia disease model by an automated and controlled process using a robotic multicellular bioprinting system
15 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 20
🏛 Institutions: King Faisal Specialist Hospital & Research Centre

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago